Halozyme Therapeutics, Inc.
IT ˙ BIT ˙ US40637H1095
58,52 € 0,00 (0,00%)
2026-06-03
AKTIENPREIS
SecurityIT:1HALO / Halozyme Therapeutics, Inc.
InstitutionUBS Group AG
Latest Disclosed Ownership914,003 shares
Latest Disclosed Value $ 59,072,013
UBS Group AG ownership in 1HALO / Halozyme Therapeutics, Inc.

On May 5, 2026 - UBS Group AG filed a 13F-HR form disclosing ownership of 914,003 shares of Halozyme Therapeutics, Inc. (IT:1HALO) valued at $49,337,882 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 29, 2026 disclosing 1,365,643 shares of Halozyme Therapeutics, Inc.. This represents a change in shares of -33.07% during the quarter. The current value of the position is $53,487,456 USD.

UBS Group AG has a history of taking positions in derivatives of the underlying security (1HALO) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD and put options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

IT:1HALO / Halozyme Therapeutics, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-05 2026-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 914,003 -451,640 -33.07 59,072 -35.73 0.0017
2026-01-29 2025-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 1,365,643 -1,580,108 -53.64 91,908 -57.46 0.0149
2025-11-13 2025-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 2,945,751 1,421,364 93.24 216,041 172.44 0.0338
2025-08-14 2025-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 1,524,387 1,173,156 334.01 79,299 253.82 0.0137
2025-05-13 2025-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 351,231 -267,543 -43.24 22,412 -24.24 0.0041
2025-02-14 2024-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 618,774 263,248 74.04 29,584 45.37 0.0055
2024-11-14 2024-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 355,526 -207 -0.06 20,350 9.26 0.0044
2024-08-14 2024-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 355,733 24,403 7.37 18,626 38.20 0.0046
2024-05-13 2024-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 331,330 -84,076 -20.24 13,479 -12.21 0.0034
2024-02-09 2023-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 415,406 227,518 121.09 15,353 113.92 0.0046
2023-11-09 2023-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 187,888 -17,439 -8.49 7,177 -3.09 0.0025
2023-08-11 2023-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 205,327 26,208 14.63 7,406 8.27 0.0025
2023-05-12 2023-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 179,119 31,735 21.53 6,841 -18.44 0.0025
2023-02-08 2022-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 147,384 98,207 199.70 8,386 331.38 0.0031
2022-11-10 2022-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 49,177 -29,695 -37.65 1,944 -43.99 0.0009
2022-08-10 2022-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 78,872 -12,022 -13.23 3,471 -4.25 0.0014
2022-05-16 2022-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 90,894 -85,419 -48.45 3,625 -48.87 0.0012
2022-02-14 2021-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 176,313 13,513 8.30 7,090 7.05 0.0020
2021-11-15 2021-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 162,800 79,807 96.16 6,623 75.77 0.0021
2021-08-13 2021-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 82,993 -78,857 -48.72 3,768 -44.15 0.0012
2021-05-12 2021-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 161,850 54,315 50.51 6,747 46.90 0.0022
2021-02-11 2020-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 107,535 37,205 52.90 4,593 148.40 0.0016
2020-11-12 2020-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 70,330 -2,170 -2.99 1,849 -4.84 0.0007
2020-07-31 2020-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 72,500 -45,050 -38.32 1,943 -8.09 0.0008
2020-05-01 2020-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 117,550 -62,932 -34.87 2,114 -33.94 0.0010
2020-02-14 2019-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 180,482 -35,637 -16.49 3,200 -4.53 0.0011
2019-11-14 2019-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 216,119 80,977 59.92 3,352 44.42 0.0013
2019-08-14 2019-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 135,142 53,259 65.04 2,321 76.10 0.0009
2019-05-14 2019-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 81,883 -120,852 -59.61 1,318 -55.56 0.0005
2019-02-14 2018-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 202,735 105,200 107.86 2,966 67.38 0.0013
2018-11-14 2018-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 97,535 30,194 44.84 1,772 55.99 0.0007
2018-08-14 2018-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 67,341 -116,215 -63.31 1,136 -68.40 0.0005
2018-05-15 2018-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 183,556 100,813 121.84 3,595 114.37 0.0016
2018-02-14 2017-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 82,743 -30,164 -26.72 1,677 -14.48 0.0007
2017-11-14 2017-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 112,907 20,876 22.68 1,961 66.19 0.0009
2017-11-14 2017-06-30 13F/A-1 HALOZYME THERAPEUTICS COM 40637H109 92,031 -12,130 -11.65 1,180 -12.59 0.0006
2017-08-14 2017-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 92,031 -12,130 1,180
2017-11-14 2017-03-31 13F/A-1 HALOZYME THERAPEUTICS COM 40637H109 104,161 -71,023 -40.54 1,350 -22.01 0.0007
2017-05-12 2017-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 104,161 -71,023 1,350
2017-02-14 2016-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 175,184 68,353 63.98 1,731 34.08 0.0010
2016-11-14 2016-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 106,831 -114,693 -51.77 1,291 -32.44 0.0008
2016-08-12 2016-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 221,524 20,403 10.14 1,911 0.31 0.0012
2016-05-12 2016-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 201,121 -107,189 -34.77 1,905 -64.35 0.0013
2016-02-16 2015-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 308,310 175,526 132.19 5,343 199.66 0.0035
2015-11-13 2015-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 132,784 5,957 4.70 1,783 -37.72 0.0013
2015-08-14 2015-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 126,827 7,789 6.54 2,863 68.41 0.0019
2015-05-14 2015-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 119,038 -2,733 -2.24 1,700 44.68 0.0012
2015-02-17 2014-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 121,771 121,771 1,175 0.0008
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2020-11-12 2020-09-30 13F HALOZYME THERAPEUTICS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2020-07-31 2020-06-30 13F HALOZYME THERAPEUTICS COM Call 278,000 2,708.08 7,453 4,087.08 n/a n/a n/a
2020-05-01 2020-03-31 13F HALOZYME THERAPEUTICS COM Call 9,900 -88.85 178 -88.69 n/a n/a n/a
2020-02-14 2019-12-31 13F HALOZYME THERAPEUTICS COM Call 88,800 1,574 n/a n/a n/a
2017-11-14 2017-03-31 13F/A HALOZYME THERAPEUTICS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2017-02-14 2016-12-31 13F HALOZYME THERAPEUTICS COM Call 19,500 193 n/a n/a n/a
2016-08-12 2016-06-30 13F HALOZYME THERAPEUTICS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2016-05-12 2016-03-31 13F HALOZYME THERAPEUTICS COM Call 163,300 1,546 n/a n/a n/a
2015-11-13 2015-09-30 13F HALOZYME THERAPEUTICS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2015-08-14 2015-06-30 13F HALOZYME THERAPEUTICS COM Call 80,000 -50.00 1,806 -20.96 n/a n/a n/a
2015-05-14 2015-03-31 13F HALOZYME THERAPEUTICS COM Call 160,000 2,285 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2015-11-13 2015-09-30 13F HALOZYME THERAPEUTICS COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2015-08-14 2015-06-30 13F HALOZYME THERAPEUTICS COM Put 80,000 6.67 1,806 68.63 n/a n/a n/a
2015-05-14 2015-03-31 13F HALOZYME THERAPEUTICS COM Put 75,000 1,071 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.